What is Ammobula?

Ammobula is a prescription medication used to manage hyperammonemia (elevated ammonia levels in the blood) in patients with urea cycle disorders (UCDs). As a nitrogen scavenger, Ammobula works by providing an alternative pathway for removing excess nitrogen from the body when the normal urea cycle is impaired.

Urea cycle disorders are rare genetic conditions that affect the body's ability to remove ammonia, a toxic byproduct of protein breakdown. Without proper treatment, elevated ammonia levels can cause serious neurological damage and life-threatening complications.

What are Urea Cycle Disorders?

The urea cycle is a series of biochemical reactions that occur primarily in the liver, converting toxic ammonia into urea, which can be safely eliminated through urine. Urea cycle disorders occur when one of the enzymes in this pathway is deficient or absent due to genetic mutations.

Types of Urea Cycle Disorders:

• Ornithine Transcarbamylase (OTC) Deficiency - The most common UCD, affecting approximately 1 in 56,000 births
• Carbamoyl Phosphate Synthetase I (CPS1) Deficiency
• Argininosuccinate Synthetase Deficiency (Citrullinemia Type I)
• Argininosuccinate Lyase Deficiency (Argininosuccinic Aciduria)
• Arginase Deficiency
• N-acetylglutamate Synthase (NAGS) Deficiency

Symptoms of Hyperammonemia:

Symptoms can range from mild to severe and may include lethargy, vomiting, confusion, behavioral changes, seizures, and in severe cases, coma. Infants with severe UCDs may present with poor feeding, vomiting, and rapid deterioration within days of birth.

How Ammobula Works - Mechanism of Action

Nitrogen Scavenging Pathway

Ammobula contains sodium phenylbutyrate, which works as a nitrogen scavenger through the following mechanism:

• After oral administration, sodium phenylbutyrate is converted to phenylacetate in the body through beta-oxidation
• Phenylacetate conjugates with glutamine to form phenylacetylglutamine
• Phenylacetylglutamine is then excreted in the urine, removing nitrogen that would otherwise be converted to ammonia
• This alternative pathway bypasses the defective urea cycle, effectively reducing ammonia levels in the blood

Each molecule of phenylacetylglutamine contains two nitrogen molecules, making this an efficient route for nitrogen disposal when the urea cycle is compromised.

FDA Approval and Clinical Evidence

Ammobula (Sodium Phenylbutyrate Oral Powder USP) is an FDA-approved prescription medication for the management of urea cycle disorders (UCDs) in patients who cannot be managed by dietary protein restriction and amino acid supplementation alone. It is approved for use across all age groups — from neonates to adults — and is classified as FDA Pregnancy Category C. The medication has been used for over two decades in the management of these rare metabolic disorders.

Primary Endpoint — Ammonia Level Reduction:

A retrospective study evaluated nine patients with OTC (ornithine transcarbamylase) deficiency treated with sodium phenylbutyrate at a median dose of 352 mg/kg/day, with a median follow-up of 26 months. Median plasma ammonia levels were maintained at 30 μmol/L and median glutamine levels at 902 μmol/L during the treatment period.

Secondary Endpoints — Hospitalizations and Hyperammonemic Crises:

During the 26-month follow-up period, there were no hyperammonemic episodes requiring hospitalization. Total protein intake was increased to 0.95 g/kg/day after 18 months of therapy, indicating improved metabolic tolerance and better quality of life.

Safety Profile:

No adverse effects related to therapy were observed during the treatment period. Neurological status in patients was mostly stable, with some mild deficits (e.g., ataxia, hyperactivity, speech delay). Liver and renal function remained normal throughout therapy. The study confirmed that sodium phenylbutyrate use in OTC-deficient patients is safe, facilitates clinical management, and enhances quality of life by achieving better metabolic control despite higher natural protein intake.

Key References:

• Luis Peña-Quintana et al. Profile of sodium phenylbutyrate granules for the treatment of urea-cycle disorders: patient perspectives. Patient Preference and Adherence 2017:11 1489–1496.
• Alberto B. Burlina et al. Long-Term Treatment with Sodium Phenylbutyrate in Ornithine Transcarbamylase-Deficient Patients. Molecular Genetics and Metabolism Volume 72, Issue 4, April 2001, Pages 351–355.
• Alberto Burlina et al. Long-Term Management of Patients with Mild Urea Cycle Disorders Identified through the Newborn Screening. Nutrients 2024, 16, 13. https://doi.org/10.3390/nu16010013
• Javier de las Heras et al. An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers. Expert Opin Drug Metab Toxicol. 2017 April; 13(4): 439–448.

Dosing and Administration

Important Prescribing Information

Ammobula is a prescription medication that must only be initiated and monitored by a metabolic specialist or physician experienced in the management of urea cycle disorders. Dosing is individualized based on body weight and body surface area. For full prescribing information, contact Laurus Rare Diseases at 7337585050 or visit www.laurusrarediseases.com/ammobula.html

Dosage Forms:

• Sodium Phenylbutyrate Oral Powder USP — available in 250 cc bottles containing 100 g of powder (Price: ₹24,500 per pack, as of November 2025)

Standard Dosing:

• Adults and children weighing >20 kg: 9.9–13 g/m² body surface area per day
• Children weighing ≤20 kg: 450–600 mg/kg per day
• Maximum daily dose should not exceed 20 grams per day

Administration Guidelines — Timing and Meal Considerations:

• The powder should be taken in equally divided amounts with each meal or feeding, three to six times per day
• Can be mixed with solid foods (applesauce, oatmeal) or liquids for immediate use
• Indicated for oral use only — via mouth, gastrostomy, or nasogastric tube (nasogastric/gastrostomy tube administration requires medical supervision)
• When dissolved in water, Ammobula Powder is stable for up to one week at room temperature or refrigerated

Storage Requirements:

• Store at room temperature between 15–30°C (59–86°F)
• Keep container tightly closed to protect from moisture; keep out of reach of children
• Do not use after the expiration date

Special Populations:

• Pediatric: Approved for use in pediatric patients including infants and newborns. Dosing is weight-based (per kg or body surface area) and requires close monitoring by a metabolic specialist.
• Pregnancy and Lactation: FDA Pregnancy Category C. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss risks and benefits with their healthcare provider, as uncontrolled hyperammonemia during pregnancy poses significant risks to both mother and baby.
• Hepatic/Renal Impairment and Cardiac Conditions: Should be used with great care, if at all, in patients with congestive heart failure or severe renal insufficiency, and in clinical states with sodium retention with edema.

Safety Profile and Side Effects

Most Common Side Effects:

• Menstrual irregularities in women
• Decreased appetite
• Body odor (described as musty or unpleasant — caused by phenylacetate metabolite; indicates medication is being metabolized properly)
• Bad taste or altered taste perception (dysgeusia)
• Nausea and vomiting
• Abdominal pain
• Headache

Most side effects are dose-related and may improve with dosage adjustment or administration with food. In clinical studies, no adverse effects were detected during the treatment period, with liver and renal function remaining normal throughout therapy.

Contraindications:

• Known hypersensitivity to sodium phenylbutyrate or any formulation component
• Acute hyperammonemic encephalopathy (requires different emergency treatment)

Drug Interactions:

• Probenecid: May affect phenylacetate excretion
• Valproate: May increase ammonia levels
• Corticosteroids: May increase protein catabolism and raise plasma ammonia levels
• Haloperidol: Potential for increased side effects. Always inform your healthcare provider of all medications being taken.

Monitoring and Laboratory Parameters

Required Monitoring:

Plasma levels of ammonia, arginine, branched-chain amino acids, and serum proteins should be maintained within normal limits, and plasma glutamine should be maintained at levels less than 1,000 μmol/L. Serum drug levels of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine, should be monitored periodically.

Treatment Landscape for UCDs

Comprehensive Management Approach:

• Dietary protein restriction and specialized medical foods
• Nitrogen scavenger medications (Ammobula/sodium phenylbutyrate)
• Essential amino acid supplementation (arginine, citrulline)
• Emergency protocols for hyperammonemic crises
• Liver transplantation in severe cases

For Healthcare Professionals

Ammobula is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency.

Resources for Healthcare Providers:

• DailyMed Prescribing Information

For Patients and Caregivers

What to Expect During Treatment:

• How to take Ammobula correctly: Mix the prescribed powder dose with food (e.g., applesauce, oatmeal) or liquid and take with each meal, three to six times daily as directed. Never adjust the dose without consulting your healthcare provider.
• What to do if a dose is missed: Take the missed dose as soon as you remember, unless it is almost time for your next scheduled dose. Do not double doses to make up for a missed one. Missing doses can increase the risk of hyperammonemic episodes, so maintaining a consistent dosing schedule is crucial.
• Recognizing signs of high ammonia levels: Warning signs of a hyperammonemic crisis include confusion or altered mental status, excessive sleepiness or lethargy, vomiting, loss of coordination, unusual behavior, difficulty walking, and in severe cases, seizures or coma. These are medical emergencies requiring immediate hospitalization.
• When to contact your healthcare provider: Contact your provider immediately during illness, infection, surgery, or physical stress, as these can trigger hyperammonemic episodes even in well-controlled patients. You may need temporary medication adjustments or increased monitoring.

Daily Management Tips:

• Medication adherence: Take Ammobula exactly as prescribed. Ensure adequate supply and refill prescriptions in advance. Never discontinue Ammobula without consulting your healthcare provider, as stopping treatment can lead to dangerous hyperammonemic crises even when ammonia levels are well-controlled.
• Dietary guidelines: Patients with UCDs require a protein-restricted diet alongside Ammobula therapy. Work with a metabolic dietitian to maintain adequate nutrition while limiting protein intake to reduce nitrogen waste production.
• Emergency preparedness: Develop an emergency protocol letter to share with all healthcare providers. Wear medical alert identification indicating the UCD diagnosis. Educate family members and caregivers to recognize signs of hyperammonemic crisis and know when to seek emergency care.
• School/work and monitoring: Keep all scheduled monitoring appointments for plasma ammonia, amino acid profiles, liver function, and blood counts. The frequency of testing depends on individual disease stability and will be determined by your metabolic specialist.

Quality of Life Considerations:

• Managing side effects: The characteristic body odor from phenylacetate metabolite is not dangerous and indicates the medication is working. Most side effects (nausea, altered taste, decreased appetite) are dose-related and may improve with dose adjustment or taking the medication with food.
• Emotional and psychological support: Living with a urea cycle disorder requires comprehensive care involving metabolic specialists, dietitians, and genetic counselors. Seek psychological support and connect with other families through patient advocacy organizations such as the National Urea Cycle Disorders Foundation (NUCDF).
• Connecting with other families: Join support groups and patient advocacy organizations including the National Urea Cycle Disorders Foundation (NUCDF), National Organization for Rare Disorders (NORD), and the Genetic and Rare Diseases Information Center (GARD) to find community, education, and support.

Patient Support and Resources

Patient Advocacy Organizations:

• National Urea Cycle Disorders Foundation (NUCDF)
• National Organization for Rare Disorders (NORD)
• Genetic and Rare Diseases Information Center (GARD)